Koji Kawamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Koji Kawamura has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Nakasone
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications - Jin Hayakawa
Affiliation Department of Biomedical Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
3 shared publications - Kazuaki Kameda
Department of Innovative Medical Science, Tokai University School of Medicine
3 shared publications - Naonori Harada
Department of Hematology, Izumiotsu Medical Center, Osaka, Japan
3 shared publications - Shinichi Kako
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications - Yoshinobu Kanda
Division of Hematology Jichi Medical University Saitama Medical Center Saitama Japan
3 shared publications
Latest Publications
- Open Access
Molecular Docking and Simulation-Based Exploration of Niclosamide as a Potential Inhibitor of the p62 ZZ Domain
Acute myeloid leukemia (AML) remains a therapeutic challenge due to complex oncogenic networks, including the often-undruggable MYC pathway. Here, we present an integrated in silico framework combining transcriptomic analysis, machine learning, and molecular dynamics (MD) simulations to explore potential therapeutic approaches targeting vault RNA1-1 (VTRNA1-1) in AML. RNA-seq profiling revealed that VTRNA1-1 depletion is associated with a profound disruption of the MYC and FOXM1 regulatory axes. To highlight compounds capable of recapitulating this transcriptomic signature, we developed a machine learning pipeline utilizing a Random Forest classifier trained on a fully compiled L1000FWD database subset. Virtual screening of approved drugs predicted the anthelmintic niclosamide as a top candidate (98.17% mimic probability). Explainable AI further rationalized this prediction by highlighting specific fragments within niclosamide’s salicylanilide core. Furthermore, a 200 ns MD simulation indicated favorable computational stability of niclosamide bound to the p62 (SQSTM1) ZZ domain. The complex showed rapid structural convergence (ligand RMSD plateauing at 1.65 nm) without dissociation, while maintaining strict receptor compactness (steady Radius of Gyration and solvent-accessible surface area) and a persistent interaction network of ~73 close atomic contacts. These findings suggest that niclosamide may function as a stable physical “lid” over the p62 ZZ domain, occluding its N-degron-binding cleft. Taken together, our computational framework highlights niclosamide as a promising candidate for AML drug repurposing, providing a hypothesis-generating foundation that warrants rigorous experimental validation.
Open AccessMolecular Docking and Simulation-Based Exploration of Niclosamide as a Potential Inhibitor of the p62 ZZ Domain
Acute myeloid leukemia (AML) remains a therapeutic challenge due to complex oncogenic networks, including the often-undruggable MYC pathway. Here, we present an integrated in silico framework combining transcriptomic analysis, machine learning, and molecular dynamics (MD) simulations to explore potential therapeutic approaches targeting vault RNA1-1 (VTRNA1-1) in AML. RNA-seq profiling revealed that VTRNA1-1 depletion is associated with a profound disruption of the MYC and FOXM1 regulatory axes. To highlight compounds capable of recapitulating this transcriptomic signature, we developed a machine learning pipeline utilizing a Random Forest classifier trained on a fully compiled L1000FWD database subset. Virtual screening of approved drugs predicted the anthelmintic niclosamide as a top candidate (98.17% mimic probability). Explainable AI further rationalized this prediction by highlighting specific fragments within niclosamide’s salicylanilide core. Furthermore, a 200 ns MD simulation indicated favorable computational stability of niclosamide bound to the p62 (SQSTM1) ZZ domain. The complex showed rapid structural convergence (ligand RMSD plateauing at 1.65 nm) without dissociation, while maintaining strict receptor compactness (steady Radius of Gyration and solvent-accessible surface area) and a persistent interaction network of ~73 close atomic contacts. These findings suggest that niclosamide may function as a stable physical “lid” over the p62 ZZ domain, occluding its N-degron-binding cleft. Taken together, our computational framework highlights niclosamide as a promising candidate for AML drug repurposing, providing a hypothesis-generating foundation that warrants rigorous experimental validation.
- Open Access
- 15 March 2026
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 65 (6) , 873-877
Localized Stage Plasmablastic Lymphoma with Ulcerative Colitis in Long-term Remission after Chemoradiotherapy
Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell lymphoma with a poor prognosis and is typically linked to HIV-related immunodeficiency. PBL associated with ulcerative colitis (UC) is an extremely rare condition. We report the case of a 63-year-old HIV-negative woman with UC who developed colonic PBL after long-term mesalazine and budesonide treatment. She achieved complete remission following chemotherapy and abdominal radiotherapy, with no recurrence for more than three years. To our knowledge, this is the fourth reported case of UC-associated PBL and demonstrates the longest survival. Chemoradiotherapy may be an effective treatment for localized PBL.
- 15 March 2026
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 65 (6) , 873-877
Open AccessLocalized Stage Plasmablastic Lymphoma with Ulcerative Colitis in Long-term Remission after Chemoradiotherapy
Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell lymphoma with a poor prognosis and is typically linked to HIV-related immunodeficiency. PBL associated with ulcerative colitis (UC) is an extremely rare condition. We report the case of a 63-year-old HIV-negative woman with UC who developed colonic PBL after long-term mesalazine and budesonide treatment. She achieved complete remission following chemotherapy and abdominal radiotherapy, with no recurrence for more than three years. To our knowledge, this is the fourth reported case of UC-associated PBL and demonstrates the longest survival. Chemoradiotherapy may be an effective treatment for localized PBL.
- 1 January 2025
- Published by Tottori University Faculty of Medicine in Yonago Acta Medica
- Vol. 68 (3) , 169-179
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been established as a curative treatment for hematological malignancies such as acute myeloid leukemia and myelodysplastic syndrome. Patients aged ≥ 70 years have traditionally been considered ineligible for this procedure, because of concerns over high transplant-related mortality rates and difficulties managing post-transplant complications. However, recent advances in supportive care, expanded donor availability, and the development of reduced-intensity conditioning (RIC) regimens have increased the availability of allo-HCT for older patients. Notably, the number of allo-HCT procedures performed in patients aged ≥ 70 has been steadily increasing in Japan and Western countries, reflecting a re-evaluation of transplant eligibility in older patients. When assessing transplant eligibility in older patients, it is crucial to consider not only disease risk stratification and treatment response, but also comprehensive evaluations of general health status, comorbidities, cognitive function, and social backgrounds. In particular, indexes such as the Hematopoietic Cell Transplantation-Comorbidity Index and Comprehensive Geriatric Assessment have proven useful for predicting patient prognoses and non-relapse mortality. Donor selection and the intensity of the conditioning regimen used can both significantly influence transplant outcomes. RIC or non-myeloablative regimens are generally recommended for patients aged ≥ 70 years. Human leukocyte antigen-matched related or younger unrelated donors are preferred, while haploidentical donors or cord blood may be considered when matched donors are unavailable, although evidence in older patients is limited. This review provides a comprehensive overview of the current status of and challenges related to allo-HCT in patients aged ≥ 70 years. Patient eligibility, conditioning strategies, donor selection, and transplant outcomes are discussed in detail, based on the latest available evidence.
- 1 January 2025
- Published by Tottori University Faculty of Medicine in Yonago Acta Medica
- Vol. 68 (3) , 169-179
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been established as a curative treatment for hematological malignancies such as acute myeloid leukemia and myelodysplastic syndrome. Patients aged ≥ 70 years have traditionally been considered ineligible for this procedure, because of concerns over high transplant-related mortality rates and difficulties managing post-transplant complications. However, recent advances in supportive care, expanded donor availability, and the development of reduced-intensity conditioning (RIC) regimens have increased the availability of allo-HCT for older patients. Notably, the number of allo-HCT procedures performed in patients aged ≥ 70 has been steadily increasing in Japan and Western countries, reflecting a re-evaluation of transplant eligibility in older patients. When assessing transplant eligibility in older patients, it is crucial to consider not only disease risk stratification and treatment response, but also comprehensive evaluations of general health status, comorbidities, cognitive function, and social backgrounds. In particular, indexes such as the Hematopoietic Cell Transplantation-Comorbidity Index and Comprehensive Geriatric Assessment have proven useful for predicting patient prognoses and non-relapse mortality. Donor selection and the intensity of the conditioning regimen used can both significantly influence transplant outcomes. RIC or non-myeloablative regimens are generally recommended for patients aged ≥ 70 years. Human leukocyte antigen-matched related or younger unrelated donors are preferred, while haploidentical donors or cord blood may be considered when matched donors are unavailable, although evidence in older patients is limited. This review provides a comprehensive overview of the current status of and challenges related to allo-HCT in patients aged ≥ 70 years. Patient eligibility, conditioning strategies, donor selection, and transplant outcomes are discussed in detail, based on the latest available evidence.
- 15 April 2023
- Published by Springer Nature in International Journal of Hematology
- Vol. 118 (2) , 193-200
Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
In the last two decades, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies have greatly improved the overall survival of patients with multiple myeloma. However, multiple myeloma remains incurable, and high-risk patients have poor long-term survival. Although allogeneic hematopoietic stem cell transplantation (allo-HCT) is not considered standard therapy because of relatively high transplant-related mortality and relapse rates, the graft-versus-myeloma (GVM) effect makes it a potentially curative therapy. Therefore, allo-HCT remains a treatment option for younger patients and those with high-risk myeloma. Maintenance therapy with novel agents has recently been attempted to reduce relapse in patients undergoing allo-HCT, but its effectiveness remains unclear. This review focuses on the role of maintenance therapy after allo-HCT in patients with myeloma. Maintenance therapy using IMiDs and/or PIs after allo-HCT may be effective in reducing relapse or improving response because it may prevent early progression before achievement of the GVM effect or enhance the GVM effect. However, care must be taken to avoid complications, such as graft-versus-host disease. Further studies are necessary to determine the optimal maintenance drugs, drug combinations, dosing, start timing, and number of cycles.
- 15 April 2023
- Published by Springer Nature in International Journal of Hematology
- Vol. 118 (2) , 193-200
Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
In the last two decades, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies have greatly improved the overall survival of patients with multiple myeloma. However, multiple myeloma remains incurable, and high-risk patients have poor long-term survival. Although allogeneic hematopoietic stem cell transplantation (allo-HCT) is not considered standard therapy because of relatively high transplant-related mortality and relapse rates, the graft-versus-myeloma (GVM) effect makes it a potentially curative therapy. Therefore, allo-HCT remains a treatment option for younger patients and those with high-risk myeloma. Maintenance therapy with novel agents has recently been attempted to reduce relapse in patients undergoing allo-HCT, but its effectiveness remains unclear. This review focuses on the role of maintenance therapy after allo-HCT in patients with myeloma. Maintenance therapy using IMiDs and/or PIs after allo-HCT may be effective in reducing relapse or improving response because it may prevent early progression before achievement of the GVM effect or enhance the GVM effect. However, care must be taken to avoid complications, such as graft-versus-host disease. Further studies are necessary to determine the optimal maintenance drugs, drug combinations, dosing, start timing, and number of cycles.
- 1 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1186-e1187
Comparison of longitudinal health-related quality of life outcomes between the anterior and posterior surgical approach to robot-assisted radical prostatectomy
- 1 March 2019
- Published by Elsevier in European Urology Supplements
- Vol. 18 (1) , e1186-e1187
Comparison of longitudinal health-related quality of life outcomes between the anterior and posterior surgical approach to robot-assisted radical prostatectomy
- 30 September 2017
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (1) , 169-179
Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin
We hypothesized that systemic corticosteroid administration would be safely avoided not only in grade I acute graft-versus-host disease (GVHD) but also in selected patients with grade II acute GVHD limited to the skin (grade IIs GVHD). We retrospectively evaluated risk factors for subsequent GVHD progression, defined as the involvement of other organs or progression to grade III to IV GVHD, in 50 patients with acute GVHD of grade IIs at its onset. Sixteen patients received systemic corticosteroid administration before GVHD progression. The cumulative incidence of GVHD progression at 28 days from the onset of grade IIs GVHD was 24%. Twenty-five patients did not require systemic corticosteroid administration throughout the entire episode of acute GVHD. Systemic corticosteroid administration before GVHD progression did not affect GVHD progression, chronic GVHD, or non-relapse mortality. Early onset (less than 26 days from transplantation) of grade IIs GVHD was identified as the only statistically significant risk factor for GVHD progression (hazard ratio 6.73, 95% confidence interval 1.5–31.1, P = 0.01). In conclusion, avoiding systemic corticosteroid administration for selected patients with grade IIs GVHD before GVHD progression did not compromise the transplantation outcomes. Patients with early-onset grade IIs GVHD were at high risk for GVHD progression.
- 30 September 2017
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (1) , 169-179
Safety of avoiding systemic corticosteroid administration for grade II acute graft-versus-host disease limited to the skin
We hypothesized that systemic corticosteroid administration would be safely avoided not only in grade I acute graft-versus-host disease (GVHD) but also in selected patients with grade II acute GVHD limited to the skin (grade IIs GVHD). We retrospectively evaluated risk factors for subsequent GVHD progression, defined as the involvement of other organs or progression to grade III to IV GVHD, in 50 patients with acute GVHD of grade IIs at its onset. Sixteen patients received systemic corticosteroid administration before GVHD progression. The cumulative incidence of GVHD progression at 28 days from the onset of grade IIs GVHD was 24%. Twenty-five patients did not require systemic corticosteroid administration throughout the entire episode of acute GVHD. Systemic corticosteroid administration before GVHD progression did not affect GVHD progression, chronic GVHD, or non-relapse mortality. Early onset (less than 26 days from transplantation) of grade IIs GVHD was identified as the only statistically significant risk factor for GVHD progression (hazard ratio 6.73, 95% confidence interval 1.5–31.1, P = 0.01). In conclusion, avoiding systemic corticosteroid administration for selected patients with grade IIs GVHD before GVHD progression did not compromise the transplantation outcomes. Patients with early-onset grade IIs GVHD were at high risk for GVHD progression.
- Open Access
- 1 July 2016
- Published by Elsevier in Asian Journal of Surgery
- Vol. 39 (3) , 187-190
Composite pheochromocytoma with a malignant peripheral nerve sheath tumor: Case report and review of the literature
- 1 July 2016
- Published by Elsevier in Asian Journal of Surgery
- Vol. 39 (3) , 187-190
Open AccessComposite pheochromocytoma with a malignant peripheral nerve sheath tumor: Case report and review of the literature
- 28 November 2014
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (6) , 930-940
Persistence of recipient‐derived as well as donor‐derived clones of cytomegalovirus pp65‐specific cytotoxic T cells long after allogeneic hematopoietic stem cell transplantation
Background: Cytomegalovirus (CMV)‐specific CD8+ cytotoxic T lymphocytes (CMV‐CTLs) play a crucial role in preventing CMV disease. However, the actual in vivo dynamics of CMV‐CTL clones after allogeneic hematopoietic stem cell transplantation (alloHCT) are still unclear.Methods: Using a single‐cell T‐cell receptor repertoire analysis, we monitored clones and chimerism of CMV‐CTLs in 3 CMV‐seropositive alloHCT recipients from CMV‐seronegative donors, with or without CMV reactivation.Results: Nearly all of the CMV‐CTLs during follow‐up were CD45RA−CCR7− effector memory/CD45RA+CCR7− effector T cells, and were highly matured. In each case, the use of BV gene families was restricted, especially in BV5, 7, 28, and 29. Although no common predominant CMV‐CTL clones were found, several shared motifs of complementarity‐determining region‐3 were identified among the 3 cases; QGA in all, TGE and TDT in Case 1 and Case 2, and RDRG in Case 2 and Case 3. In all cases, CMV‐CTL clones that were detected for the first time after alloHCT persisted as the dominant clones. In Case 1, without CMV reactivation, recipient‐derived CMV‐CTLs exclusively persisted as a dominant clone, while all CMV‐CTLs in the other 2 cases, with CMV reactivation, were donor derived.Conclusion: Clone monitoring and chimerism analyses should help to further clarify novel aspects of immuno‐reconstitution after alloHCT.
- 28 November 2014
- Published by Wiley in Transplant Infectious Disease
- Vol. 16 (6) , 930-940
Persistence of recipient‐derived as well as donor‐derived clones of cytomegalovirus pp65‐specific cytotoxic T cells long after allogeneic hematopoietic stem cell transplantation
Background: Cytomegalovirus (CMV)‐specific CD8+ cytotoxic T lymphocytes (CMV‐CTLs) play a crucial role in preventing CMV disease. However, the actual in vivo dynamics of CMV‐CTL clones after allogeneic hematopoietic stem cell transplantation (alloHCT) are still unclear.Methods: Using a single‐cell T‐cell receptor repertoire analysis, we monitored clones and chimerism of CMV‐CTLs in 3 CMV‐seropositive alloHCT recipients from CMV‐seronegative donors, with or without CMV reactivation.Results: Nearly all of the CMV‐CTLs during follow‐up were CD45RA−CCR7− effector memory/CD45RA+CCR7− effector T cells, and were highly matured. In each case, the use of BV gene families was restricted, especially in BV5, 7, 28, and 29. Although no common predominant CMV‐CTL clones were found, several shared motifs of complementarity‐determining region‐3 were identified among the 3 cases; QGA in all, TGE and TDT in Case 1 and Case 2, and RDRG in Case 2 and Case 3. In all cases, CMV‐CTL clones that were detected for the first time after alloHCT persisted as the dominant clones. In Case 1, without CMV reactivation, recipient‐derived CMV‐CTLs exclusively persisted as a dominant clone, while all CMV‐CTLs in the other 2 cases, with CMV reactivation, were donor derived.Conclusion: Clone monitoring and chimerism analyses should help to further clarify novel aspects of immuno‐reconstitution after alloHCT.
- Open Access
- 1 January 2011
- Published by Wiley in Prostate Cancer
- Vol. 2011, 1-6
Development and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer
Objective. The aim of this study is to develop a prognostic model capable of predicting the probability of significant upgrading among Japanese patients.Methods. The study cohort comprised 508 men treated with RP, with available prostate-specific antigen levels, biopsy, and RP Gleason sum values. Clinical and pathological data from 258 patients were obtained from another Japanese institution for validation.Results. Significant Gleason sum upgrading was recorded in 92 patients (18.1%) at RP. The accuracy of the nomogram predicting the probability of significant Gleason sum upgrading between biopsy and RP specimens was 88.9%. Overall AUC was 0.872 when applied to the validation data set. Nomogram predictions of significant upgrading were within 7.5% of an ideal nomogram.Conclusions. Nearly one-fifth of Japanese patients with prostate cancer will be significantly upgraded. Our nomogram seems to provide considerably accurate predictions regardless of minor variations in pathological assessment when applied to Japanese patient populations.
- 1 January 2011
- Published by Wiley in Prostate Cancer
- Vol. 2011, 1-6
Open AccessDevelopment and External Validation of a Nomogram Predicting the Probability of Significant Gleason Sum Upgrading among Japanese Patients with Localized Prostate Cancer
Objective. The aim of this study is to develop a prognostic model capable of predicting the probability of significant upgrading among Japanese patients.Methods. The study cohort comprised 508 men treated with RP, with available prostate-specific antigen levels, biopsy, and RP Gleason sum values. Clinical and pathological data from 258 patients were obtained from another Japanese institution for validation.Results. Significant Gleason sum upgrading was recorded in 92 patients (18.1%) at RP. The accuracy of the nomogram predicting the probability of significant Gleason sum upgrading between biopsy and RP specimens was 88.9%. Overall AUC was 0.872 when applied to the validation data set. Nomogram predictions of significant upgrading were within 7.5% of an ideal nomogram.Conclusions. Nearly one-fifth of Japanese patients with prostate cancer will be significantly upgraded. Our nomogram seems to provide considerably accurate predictions regardless of minor variations in pathological assessment when applied to Japanese patient populations.